Lupin jumps on launching Authorized Generic Version of Alinia
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 1056.00, up by 24.30 points or 2.36% from its previous closing of Rs. 1031.70 on the BSE.
The scrip opened at Rs. 1049.75 and has touched a high and low of Rs. 1062.15 and Rs. 1036.70 respectively. So far 52511 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 1067.90 and Rs. 1014.65 respectively. The current market cap of the company is Rs. 47957.67 crore.
The promoters holding in the company stood at 46.88%, while Institutions and Non-Institutions held 40.05% and 12.79% respectively.
Lupin has launched the authorized generic version of Alinia (nitazoxanide) Tablets, 500 mg of Romark Laboratories, L.C. Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
